Aventis and Watson Reach Settlement on Litigation
Aventis Pharma AG, the pharmaceutical company of Aventis, announced today that it has settled litigation with Watson Pharmaceuticals Inc. related to the hypertension drug Dilacor® XR (dilatizem).
Terms of the settlement were not material to the financial position of Aventis, which previously had recorded reserves for potential liability in connection with the dispute.
The settlement relates to a lawsuit filed by Watson in a U.S. District Court in California in August 1999 against Rhone Poulenc Rorer Inc., a predecessor company of Aventis. The lawsuit alleged breach of a manufacturing and supply agreement and a non-compete clause contained in a 1997 license agreement granting certain rights to Dilacor XR® to Watson.
Most read news
Other news from the department science

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.